Prevalence of Occult Hepatitis B and Hepatitis C Virus Infections in Turkish Hemodialysis Patients

Figures & data

Table 1 Prevalence of HBV and HCV infections

Screening test (n=188)	Positivity n (%)
HBsAg	25 (13.3)
HBV-DNA	4 (16.0)
Anti-HBc	84 (44.7)
“Isolated anti-HBc”	12 (6.4)
HBV-DNA	2 (16.7)
Occult hepatitis B	5 (2.7)
“Isolated anti-HBc”	2 (40)
Anti-HCV	38 (20.2)
HCV-RNA	21 (55.3)
“Isolated anti-HBc”	3 (7.9)
Occult hepatitis C	9 (4.8)
Dual infection	7 (3.7)

Table 2 Clinical features of the patients depending on occult HBV and occult HCV infections

	Occult HBV-positive (n=5)	Occult HBV-negative (n=183)	p	Occult HCV-Positive (n=9)	Occult HCV-Negative (n=179)	p
Age (years)	44.0±22.8	49.3±13.6	NS	50.2±12.2	49.1±14.0	NS
Gender (F:M)	2:3	84:99	NS	2:7	84:95	NS
Dialysis period (months)	34±22.8	62±49.2	NS	74±43.2	61±48.5	NS
Anti-HCV	0	38 (20.8)	NS
Isolated anti-HBc	2 (40)	10 (5.5)	0.002	1(11.1)	11 (6.1)	NS

Data are given as mean ± SD or n (%).

NS: not significant, F: female, M: male.

Table 3 Aminotransferase levels in maintenance hemodialysis patients

	HBV viremia-negative (n=179)	HBV viremia-positive (nonoccult) (n=4)	HBV viremia-positive (occult) (n=5)	p	HCV viremia-negative (n=158)	HCV viremia-positive (nonoccult) (n=21)	HCV viremia-positive (occult) (n=9)	p
AST (mean, IU/L)	16.7±16.8	12.0±3.2	12.0±1.4	NS	15.8±16.8	22.8±16.3	12.9±3.9	NS
ALT (mean, IU/L)	17.0±16.4	13.5±5.1	12.8±1.9	NS	15.4±12.9	27.6±29.8	16.3±6.2	0.004

AST: aspartate aminotransferase, ALT: alanine aminotransferase, NS: not significant.